五星体育直播

五星体育直播 Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID鈩� (nirmatrelvir tablets; ritonavir tablets)

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient (API) in PAXLOVID鈩�, Pfizer鈥檚 antiviral therapeutic, which is currently authorized for emergency use by the U.S. Food and Drug Administration (鈥淔DA鈥�) for the treatment of mild-to-moderate COVID-19 in people at high risk of progression to severe illness and authorized or approved by other regulatory authorities across the globe.

鈥淧fizer has played a critical role in the response to the global COVID-19 pandemic, including through their rapid development of PAXLOVID鈩�, and I am incredibly proud that 五星体育直播鈥� engineered enzyme is enabling a sustainable manufacturing route for their nirmatrelvir API,鈥� said John Nicols, President and CEO of 五星体育直播. 鈥淭his agreement demonstrates the agility of 五星体育直播鈥� commercial supply chain and manufacturing capabilities to very rapidly generate unprecedented enzyme quantities. We look forward to our continued support of Pfizer鈥檚 manufacturing of PAXLOVID鈩� for COVID-19 patients.鈥�

鈥溛逍翘逵辈� has been an extremely valuable partner throughout the scale-up of the nirmatrelvir process, and we are pleased to extend our partnership through this multi-year agreement,鈥� said Pamela Siwik, Vice President, Launch Excellence, Pfizer Global Supply. 鈥淭heir unique enzyme is an important element in the manufacture of PAXLOVID鈩� and plays a role in supporting our efforts to ensure rapid availability of this COVID-19 oral treatment to people around the world.鈥�

For important information related to the terms of the enzyme supply agreement and its impact on 五星体育直播鈥� outlook, see 五星体育直播鈥� Current Report on Form 8-K filed with the SEC on July 14, 2022.

About 五星体育直播

五星体育直播 is a leading enzyme engineering company leveraging its proprietary CodeEvolver庐 platform to discover and develop novel, high performance enzymes and novel biotherapeutics. 五星体育直播 enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and oral enzyme therapies. The company鈥檚 unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. 五星体育直播 enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding 五星体育直播, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including 五星体育直播鈥� expectations regarding the supply of its proprietary high performance enzyme to Pfizer and 五星体育直播鈥� ability to continue to support the manufacture of Pfizer鈥檚 treatment for COVID-19 patients. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on February 28, 2022 and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the SEC on May 9, 2022, including under the caption 鈥淩isk Factors,鈥� and in 五星体育直播鈥� other periodic reports filed with the SEC. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Relations Contact:

Argot Partners
Brendan Strong/Carrie McKim
(212) 600-1902

Released July 14, 2022